Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02354586 · BASELINE

Baseline characteristics

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens · Source last updated 2022-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      463
    units
    Participants
groups
  1. description
    Participants received Niraparib (300 milligram \[mg\], taken as 3 capsules of 100 mg once daily \[QD\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.
    id
    BG000
    title
    Niraparib 300 mg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.28
          value
          64.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          463
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          394
        title
        White
      2. measurements
        1. group Id
          BG000
          value
          20
        title
        Black
      3. measurements
        1. group Id
          BG000
          value
          16
        title
        Asian
      4. measurements
        1. group Id
          BG000
          value
          1
        title
        American Indian or Alaska Native
      5. measurements
        1. group Id
          BG000
          value
          32
        title
        Unknown
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
Baseline characteristics were reported for Safety Population.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      463
    units
    Participants
groups
  1. description
    Participants received Niraparib (300 milligram \[mg\], taken as 3 capsules of 100 mg once daily \[QD\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.
    id
    BG000
    title
    Niraparib 300 mg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.28
          value
          64.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          463
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          394
        title
        White
      2. measurements
        1. group Id
          BG000
          value
          20
        title
        Black
      3. measurements
        1. group Id
          BG000
          value
          16
        title
        Asian
      4. measurements
        1. group Id
          BG000
          value
          1
        title
        American Indian or Alaska Native
      5. measurements
        1. group Id
          BG000
          value
          32
        title
        Unknown
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
Baseline characteristics were reported for Safety Population.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice